Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.6 USD | -1.99% | -1.26% | +22.11% |
Apr. 19 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
Apr. 01 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.11% | 2.22B | |
+4.55% | 2,894B | |
+1.29% | 80.94B | |
+0.80% | 75.01B | |
-16.29% | 52.08B | |
+26.53% | 48.93B | |
-27.79% | 44.85B | |
+17.68% | 40.49B | |
+52.58% | 36.29B | |
-10.97% | 24.36B |
- Stock Market
- Equities
- CLBT Stock
- News Cellebrite DI Ltd.
- Cellebrite Launches FedRAMP Authorization Process for SaaS Offerings